Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

In 2019, the first CRISPR clinical trials were conducted to treat sickle cell diseases and in 2020, this treatment was ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

Many CRISPR-based therapies use nucleases derived from bacteria. About 80% of people have ... to the original nucleases, but still cut DNA at the same efficiency. Minimally immunogenic nucleases ...

A new study from Tel Aviv University (TAU) reveals how bacterial defense mechanisms could be neutralized during genetic material exchange, potentially enabling scientists to solve the crisis of ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to cut, replace, or delete mutations in DNA. It can also modify gene ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This achievement is a reflection of our collective efforts and ...

After more than a decade of work, researchers have reached a major milestone in their efforts to re-engineer life in the lab, putting together the final chromosome in a synthetic yeast (Saccharomyces ...

In 2012 American biochemist Jennifer Doudna and her collaborator, Emmanuelle Charpentier, proposed that CRISPR – a group of genes and molecules used by bacteria to recognise and destroy viral DNA – ...